Division of Health Service Regulation

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION		(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:		(X2) MULTIPLE CONSTRUCTION A. BUILDING:			(X3) DATE SURVEY COMPLETED					
MHL047-174		B. WING			R 08/29/2023							
NAME OF I	PROVIDER OR SUPPLIER		STREET AD	DRESS, CITY, S	STATE, ZIP CODE	1 00/1	20/2020					
MULTICULTURAL RESOURCES CENTER GROI 6188 ARABIA ROAD LUMBER BRIDGE, NC 28357												
	Г					FOTION	()(5)					
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)		ID PREFIX TAG	PROVIDER'S PLAN OF CORE (EACH CORRECTIVE ACTION S CROSS-REFERENCED TO THE AI DEFICIENCY)	TION SHOULD BE COMPLÉTE THE APPROPRIATE DATE							
V 000	0 INITIAL COMMENTS			V 000								
	completed on Augusurvey was unsubstance #NC0025741). Def This facility is licens category: 10A NCA Living for Adults with	riciencies were cited. sed for the following s AC 27G. 5600C Super h Developmental Disa	nplaint ervice rvised abilities.									
	This facility is licensed for four and currently has a census of three. The survey sample consisted of audits of 3 current clients.											
V 121	27G .0209 (F) Medication Requirements 10A NCAC 27G .0209 MEDICATION REQUIREMENTS (f) Medication review: (1) If the client receives psychotropic drugs, the governing body or operator shall be responsible for obtaining a review of each client's drug regimen at least every six months. The review shall be to be performed by a pharmacist or physician. The on-site manager shall assure that the client's physician is informed of the results of the review when medical intervention is indicated. (2) The findings of the drug regimen review shall be recorded in the client record along with corrective action, if applicable.		V 121									
	facility failed to com review for one of th	et as evidenced by: views and interview, t aplete psychotropic dr ree audited clients (# pic drugs. The finding	ug 2) who									

Division of Health Service Regulation
LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE

TITLE (X6) DATE Division of Health Service Regulation

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION (X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: MHL047-174			` ′	E CONSTRUCTION	(X3) DATE SURVEY COMPLETED	
		B. WING		R 08/29/2023		
	PROVIDER OR SUPPLIER JLTURAL RESOURCE	S CENTER GROU	DDRESS, CITY, S ABIA ROAD BRIDGE, NO	STATE, ZIP CODE		
(X4) ID PREFIX TAG	(EACH DEFICIENCY	TEMENT OF DEFICIENCIES 'MUST BE PRECEDED BY FULL SC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY) (X5) COMPLETE DATE		
V 121	-Admission date of -Diagnoses of Schiz Intellectual Develop -There was no evid psychotropic drug r Review on 8/24/23 dated 5/24/23 revea -Quetiapine 200 miduring the dayClozapine 50mg-1-Clozapine 200mg-with 50mg) -Quetiapine 300mg-Invega Sust Injecti (234mg) intramusor (234mg) intramusor Review on 8/24/23 months of June 202 revealed: -Client #2 was adm medications from J 2023. Interview on 8/24/23 revealed: -Client #2 just had a and staff should had documentationStaff that attended were responsible for is completed and refile in their records.	of client #2's record revealed: 6/17/22. Zoaffective Disorder and Mild omental Disability. ence of a current six-month eview. of client #2's physician's order aled: lligram (mg)- Take 1 tablet Take 1 tablet three times a day Take 1 tablet at bedtime (take - Take 1 tablet at bedtime on 234mg/1.5 ml- Inject 1.5ml ularly every 3 weeks. of client #2's MARS for the 23 through August 24, 2023 inistered the above une 2023 through August 24, 3 with the Facility Director an appointment this morning we brought back the appointment with clients or ensuring the documentation eturned back to the facility to beychotropic drug review for			TION SHOULD BE COMPLÉ THE APPROPRIATE DATE	

6899

Division of Health Service Regulation STATE FORM

NUD011 If continuation sheet 2 of 2